The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and one IL-17 inhibitor (Novartis’s Cosentyx). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, they face a competitive threat, both from the launch of cost-effective biosimilars and from the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in March 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation. The impending entry of additional IL-17 inhibitors (Eli Lilly’s Taltz and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapy for this indication (Pfizer’s Jak inhibitor Xeljanz) will also shift market dynamics.

Questions answered:

  • How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
  • What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
  • What pipeline products are the most promising, and what sales / uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research

Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations

Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2028, segmented by brands/generics and epidemiological subpopulations

Emerging therapies: Phase III/PR: 3 drugs; Phase II: 5 drugs

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • December 2018
      • June 2019
      • August 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Axial Spondyloarthritis?
        • What Factors Are Constraining the Market for Axial Spondyloarthritis?
      • Drug-Class Specific Trends
        • NSAIDs
        • TNF-Alpha Inhibitors
        • IL-17 Inhibitors
        • Jak Inhibitors
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Classification Criteria in Axial Spondyloarthritis
      • Presentation and Disease Progression
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Axial Spondyloarthritis
        • Total Prevalent Cases of Ankylosing Spondylitis
        • Total Prevalent Cases of Nonradiographic Axial Spondyloarthritis
        • HLA-B27 Status
        • Diagnosed Prevalent Cases of Axial Spondyloarthritis
        • Drug-Treated Cases of Axial Spondyloarthritis
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • NSAIDs
        • Conventional DMARDs
        • TNF-Alpha Inhibitors
        • IL-17 Inhibitors
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Axial Spondyloarthritis
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Axial Spondyloarthritis
        • IL-17 Inhibitors
        • Jak Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Axial Spondyloarthritis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Axial Spondyloarthritis Bibliography

Author(s): Qinghui Yu, PhD; Maria Genco, Ph.D; Mudasir Khan, M.P.H

Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science ;Qinghui Yu holds a in Neuroscience from Columbia University.

Maria Genco, is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her and in neuroscience from Brandeis University and a in neuroscience from Wellesley College.

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.


Related Reports

Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis (US)

The axial spondyloarthritis market is undergoing rapid change as physicians increasingly recognize both ankylosing spondylitis (AS) and non-radiographi...

View Details

Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis : Current Treatment: Physician Insights (EU5)

The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (

View Details

Axial Spondyloarthritis | Unmet Need | Detailed, Expanded Analysis (US & EU) : Non-radial axial spondyloarthritis : (US & EU5)

MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen&rsqu...

View Details

Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis: Ankylosing Spondylitis: Treatment Algorithms: Claims Data Analysis

MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back...

View Details